Betuvax has completed preclinical trials of a vaccine for cat allergies

Betuvax, a company within the Arthgen Biotech group, has completed preclinical studies of a new drug Betufeld for the treatment of cat allergies. Studies on mice have confirmed the high specific activity and safety of the drug. Betuvax is currently finalizing the regulatory dossier. Within a year, the company plans to obtain approval from the Ministry of Health for clinical trials and launch Phase I trials.